[go: up one dir, main page]

CR20190401A - Dropropizina en combinación con ambroxol en la forma farmacéutica de jarabe y tabletas - Google Patents

Dropropizina en combinación con ambroxol en la forma farmacéutica de jarabe y tabletas

Info

Publication number
CR20190401A
CR20190401A CR20190401A CR20190401A CR20190401A CR 20190401 A CR20190401 A CR 20190401A CR 20190401 A CR20190401 A CR 20190401A CR 20190401 A CR20190401 A CR 20190401A CR 20190401 A CR20190401 A CR 20190401A
Authority
CR
Costa Rica
Prior art keywords
dropropizine
ambroxol
combination
relates
pharmaceutically acceptable
Prior art date
Application number
CR20190401A
Other languages
English (en)
Inventor
Vázquez Jorge Luis Espino
Original Assignee
Productos Farm S A De C V
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Productos Farm S A De C V filed Critical Productos Farm S A De C V
Publication of CR20190401A publication Critical patent/CR20190401A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Emergency Medicine (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se refiere a una combinación farmacéutica de ambroxol o una sal farmacéuticamente aceptable del mismo y dropropizina. Asimismo, se refiere a una composición farmacéutica, preferentemente en una forma de administración oral, que contiene dichos ingredientes activos, junto con uno o más aditivos farmacéuticamente aceptables. La invención también se refiere a los procesos de preparación y los procesos de uso de la combinación farmacéutica o la composición farmacéutica de la presente invención.The present invention relates to a pharmaceutical combination of ambroxol, or a pharmaceutically acceptable salt of same, and dropropizine. The invention also relates to a pharmaceutical composition, preferably in an oral administration form, which contains said active ingredients together with one or more pharmaceutically acceptable additives. The invention further relates to methods for preparing and using the pharmaceutical combination or the pharmaceutical composition of the present invention.
CR20190401A 2017-11-16 2018-04-19 Dropropizina en combinación con ambroxol en la forma farmacéutica de jarabe y tabletas CR20190401A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
MX2017014725A MX2017014725A (es) 2017-11-16 2017-11-16 Dropropizina en combinacion con ambroxol en la forma farmaceutica de jarabe y tabletas.
PCT/IB2018/052699 WO2019097309A1 (es) 2017-11-16 2018-04-19 Dropropizina en combinación con ambroxol en la forma farmacéutica de jarabe y tabletas

Publications (1)

Publication Number Publication Date
CR20190401A true CR20190401A (es) 2019-11-18

Family

ID=66538528

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20190401A CR20190401A (es) 2017-11-16 2018-04-19 Dropropizina en combinación con ambroxol en la forma farmacéutica de jarabe y tabletas

Country Status (9)

Country Link
US (2) US20210128496A1 (es)
CL (1) CL2019002446A1 (es)
CO (1) CO2019013645A2 (es)
CR (1) CR20190401A (es)
DO (1) DOP2019000233A (es)
MX (1) MX2017014725A (es)
NI (1) NI201900084A (es)
PE (1) PE20191820A1 (es)
WO (1) WO2019097309A1 (es)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1203721B (it) * 1983-12-29 1989-02-23 Dompe Farmaceutici Spa Composti otticamente attivi ad attivita' antitosse e sedativa centrale,procedimento per la preparazione e composizioni che li contengono
DE19933148A1 (de) * 1999-07-20 2001-01-25 Boehringer Ingelheim Int Ambroxolhaltige Lutschtablette
KR101915056B1 (ko) * 2012-04-10 2018-11-07 한미약품 주식회사 암브록솔, 레보드로프로피진 및 완충제를 포함하는 경구용 액상 제제 및 이의 제조방법

Also Published As

Publication number Publication date
DOP2019000233A (es) 2019-12-15
NI201900084A (es) 2020-04-02
CO2019013645A2 (es) 2020-01-17
MX2017014725A (es) 2019-05-17
CL2019002446A1 (es) 2019-12-13
WO2019097309A1 (es) 2019-05-23
PE20191820A1 (es) 2019-12-27
US20240082176A1 (en) 2024-03-14
US20210128496A1 (en) 2021-05-06

Similar Documents

Publication Publication Date Title
MX2015009772A (es) Moduladores de receptores nmda de espiro-lactama y sus usos.
MX2020013116A (es) Sales y cristales novedosos.
CO2019000938A2 (es) Moduladores nmda espiro-lactam y métodos de uso de los mismos
CO2019000945A2 (es) Moduladores del receptor nmda espiro-lactam y uso de los mismos
CL2016001411A1 (es) Unidad de dosificación farmacéutica solida de desintegración oral que comprende un componente de estetrol; metodo de preparación; uso para la anticoncepción femenina y en terápia de sustitución hormonal femenina.
CO2019000943A2 (es) Moduladores del receptor nmda espiro-lactam y uso de los mismos
CO2019000941A2 (es) Moduladores del receptor nmda espiro-lactam y uso de los mismos
DOP2016000254A (es) Formulaciones farmeceuticas de inhibidor de la quinasa pan-raf, procedimientos para su preparacion, y metodos de uso.
CO2019000944A2 (es) Moduladores del receptor nmda spiro-lactam y bis-spiro-lactam y uso de los mismos
GT201700270A (es) Unidad de dosificación orodispersable que contiene un componente estetrol
MX385518B (es) FORMULACIÓN QUE TIENE CARACTERÍSTICAS MEJORADAS DE LIBERACIÓN DE FÁRMACOS pH DEPENDIENTES, QUE CONTIENEN ESOMEPRAZOL O UNA DE SUS SALES FARMACÉUTICAS ACEPTABLE.
MX2022015629A (es) Uso de vibegron para tratar vejiga sobreactiva.
MX368735B (es) (r)-pirlindol y sus sales farmaceuticamente aceptables para uso en medicina.
MX2018014184A (es) Triple combinacion de antagonistas del receptor de 5-ht6 puro, inhibidores de acetilcolinesterasa y antagonista del receptor de nmda.
CO2018013792A2 (es) Regímenes de dosificación de vortioxetina para el rápido inicio del efecto antidepresivo
CR20190401A (es) Dropropizina en combinación con ambroxol en la forma farmacéutica de jarabe y tabletas
AR115724A1 (es) Composición farmacéutica que contiene un péptido
CO2019008347A2 (es) Composición de liberación rápida de cinitaprida y simeticona y proceso para prepararla
MX372644B (es) Una combinacion de unidades de dosificacion para su uso en el tratamiento del parto prematuro.
PE20151431A1 (es) Formulaciones de lorazepam de liberacion controlada
AR099330A1 (es) Uso de paricalcitol en el tratamiento de la anemia inflamatoria
EA202092800A1 (ru) Фармацевтическая композиция немедленного высвобождения для противовоспалительных лекарственных средств с фамотидином и карбонатом
UY35324A (es) Composiciones farmacéuticas que contienen dexketoprofeno y tramadol
UA97982U (uk) Лікарський засіб седативної дії у вигляді таблеток
MX2015009504A (es) Composicion farmaceutica de desloratadina para ser administrada por via oral, para el tratamiento de enfermedades relacionadas con la histamina.